Torsten Nielsen

Aims The LUMINA trial demonstrated a very low local recurrence rate in women ≥55 years with low‐risk luminal A breast cancer (defined as grade I‐II, T1N0, hormone receptor positive, HER2 negative and Ki67 index ≤13.25%) treated with breast‐conserving surgery and endocrine therapy (but no other systemic therapy), supporting the safe omission of radiation in these women. Here we describe the protocol for Ki67 assessment, the companion diagnostic used to guide omission of adjuvant radiotherapy. Methods Ki67 immunohistochemistry was performed on full‐face sections at one of three regional labs. Pathologists trained in the International Ki67 in Breast Cancer Working Group (IKWG) method demarcated tumour areas on scanned slides and scored 100 nuclei from each of at least five randomly selected 1‐mm fields. For cases with high Ki67 heterogeneity, further virtual cores were selected and scored in order to confidently assign a case as luminal A (≤13.25%) or B (>13.25%). Interlaboratory variability was assessed through an annual quality assurance programme during the study period. Results From the quality assurance programme, the mean Ki67 index across all cases/labs was 13%. The observed intraclass correlation coefficient (ICC) and kappa statistics were ≥0.9 and ≥0.7, respectively, indicating a substantial level of agreement. Median scoring time was 4 min per case. The IKWG‐recommended scoring method, performed directly from slides, requiring up to four scored fields, is concordant with the LUMINA scoring method (ICC ≥ 0.9). Conclusion Ki67 is a practical, reproducible, and inexpensive biomarker that can identify low‐risk luminal A breast cancers as potential candidates for radiation de‐escalation. Clinical trial registration ClinicalTrials.gov number, NCT01791829